THs increase JAK/STAT pathway aberrant activation in TCL via integrin αvβ3. (A) Representative western blot results of p-STAT1 (Y701), p-STAT3 (Y705), and p-STAT5 (Y694) after 15 minutes of treatment with THs and in the presence or absence of the JAK1/2 inhibitor, Ruxo. (B) Representative western blot results of p-STATs levels after 15 minutes of treatment with THs and in the presence or absence of the integrin αvβ3 inhibitor, Cile. (C) mRNA levels of GATA3, MMP2, MMP9, CCND1, and CCR4 genes after 6-hour treatment. (D) Representative images of gelatin zymography of MMP2 and MMP9 activity measured in supernatants of TCL cells treated for 24 hours with THs, Cile, and the STAT3 inhibitor, Crypto. Ruxo = 1 μM, Cile = 3 μM, and Crypto = 1 μM for CUTLL1; 2.5 μM for OCI-LY13.2; 5 μM for OCI-LY12; and 1 μM for EL4 cells. THs include: T3 = 1 nM and T4 = 100 nM. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001 vs Veh #P < .05; ##P < .01; ###P < .001; ####P < .0001 vs THs. Crypto, cryptotanshinone; THs, thyroid hormones; p-STAT1, phosphorylated STAT1; THC, thyroid hormones + Cile; THR, thyroid hormones + Ruxo.